10q10k10q10k.net
Penumbra Inc

Penumbra IncPENEarnings & Financial Report

NYSE

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

PEN Q3 2025 Key Financial Metrics

Revenue

$354.7M

Gross Profit

$240.4M

Operating Profit

$48.8M

Net Profit

$45.9M

Gross Margin

67.8%

Operating Margin

13.8%

Net Margin

12.9%

YoY Growth

17.8%

EPS

$1.17

Financial Flow

Penumbra Inc Q3 2025 Financial Summary

Penumbra Inc reported revenue of $354.7M for Q3 2025, with a net profit of $45.9M (12.9% margin). Cost of goods sold was $114.3M, operating expenses totaled $191.6M.

Key Financial Metrics

Total Revenue$354.7M
Net Profit$45.9M
Gross Margin67.8%
Operating Margin13.8%
Report PeriodQ3 2025

Penumbra Inc Annual Revenue by Year

Penumbra Inc annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.2B).

YearAnnual Revenue
2024$1.2B
2023$1.1B
2022$847.1M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$284.7M$278.7M$299.4M$301.0M$315.5M$324.1M$339.5M$354.7M
YoY Growth28.7%15.4%14.5%11.1%10.8%16.3%13.4%17.8%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$1.56B$1.58B$1.53B$1.48B$1.53B$1.59B$1.67B$1.74B
Liabilities$377.4M$376.3M$373.3M$374.8M$382.3M$380.4M$380.9M$385.7M
Equity$1.18B$1.20B$1.16B$1.10B$1.15B$1.21B$1.29B$1.36B

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$36.3M$38.3M$22.6M$56.5M$51.1M$49.0M$44.9M$58.3M